DVA

NEUTRALEarnings

DaVita Inc.

2026-07-29

Price

$240.96

+0.63%

This is the 2026-07-29 snapshot — the signals and analysis for DVA as of this single trading day.

View full DVA research hub →

Score5.2Watchlist

Signals5/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.0xvs 20d avg

Analysis

DaVita (DVA) is exhibiting High-Conviction Price Discovery, shrugging off a tense geopolitical macro regime to hover near all-time highs. The stock's robust relative strength (+10.9% vs SPY) and PERFECT_STACK signals indicate institutional absorption into defensive, non-cyclical healthcare names amidst Middle East tensions. Buoyed by its Integrated Kidney Care (IKC) profitability and AI-driven margin expansion narratives, buyers are aggressively accumulating ahead of the upcoming August 4 earnings report.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKWEAK FINISH

Key Takeaways

Defensive Rotation: DVA's +10.9% relative strength confirms institutional capital is seeking shelter in non-cyclical healthcare amid geopolitical oil shocks.
Fundamental Catalyst: The August 4 earnings report is highly anticipated following Q1's raised guidance and the structural profitability of DVA's Integrated Kidney Care (IKC) platform.
Key Risk: Potential GLP-1 headwinds and shifts in payer mix remain structural threats that could squeeze long-term free cash flow if management's guidance falters.

← Back to 2026-07-29 View Full DVA History →Yahoo Finance &nearr;